ArticleAnnals of surgery open : perspectives of surgical history, education, and clinical approaches2026
Clinical Value of a 51-Neuroendocrine Tumor-Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery.
Article in Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To prospectively evaluate the clinical utility of NETest2.0, a 51-neuroendocrine tumor (NET)-specific gene whole blood assay (NETest2.0) for monitoring surgical patients with gastroenteropancreatic NETs (GEPNET). Background: GEPNETs are challenging regarding postoperative surveillance and monitoring for recurrence or progression. Methods: Blood samples were collected at baseline and during follow-up, and NETest2.0 was measured (scored 0-100; cutoff normal: <50) in 82 consecutive patients with GEPNET. Scores were correlated with follow-up and disease status, including no evidence of disease, stable disease, recurrent disease, and progressive disease. Results: Pancreatic NET (n = 29): median age, 57 (26-81) years, M:F (17:12), G1: 19, G2: 8, G3: 2, stages I to III (n = 18), and stage IV (n = 11). Median follow-up, 122 (4-163) months; 7 (24%) died. NETest2.0 correlated with outcomes and was significantly higher in those who died ( Conclusions: NETest2.0 accurately identified disease status and correlated with clinical outcomes. Patients were stratified into molecular remission, stable disease, and high-risk progression states. Low scores (<50) identified surgical patients unlikely to recur; scores ≥65 identified individuals at increased risk for progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.